NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Scancell Holdings plc (F: SCP)

 
SCP Technical Analysis
3
As on 12th Sep 2025 SCP STOCK Price closed @ 0.12 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.12 & Buy for SHORT-TERM with Stoploss of 0.09 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

SCPSTOCK Price

Open 0.07 Change Price %
High 0.12 1 Day 0.06 100.00
Low 0.07 1 Week -0.01 -7.69
Close 0.12 1 Month 0.04 50.00
Volume 3000 1 Year 0.02 20.00
52 Week High 0.23 | 52 Week Low 0.06
 
F Germany Most Active Stocks
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
ENB 47.60 -0.92%
TEF 3.84 -0.52%
TEF 3.84 -0.52%
WHL 5150.00 -0.44%
WDI 0.05 -37.50%
 
F Germany Top Gainers Stocks
JYR 1000000.00 10000000000.00%
JYR 1000000.00 10000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
DML 1.56 15500.00%
DML 1.56 15500.00%
0AI 11.30 14025.00%
0AI 11.30 14025.00%
 
F Germany Top Losers Stocks
TINC 0.01 -99.92%
TINC 0.01 -99.92%
TINC 0.01 -99.92%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
LDB 1.71 -92.57%
 
 
SCP
Daily Charts
SCP
Intraday Charts
Whats New @
Bazaartrend
SCP
Free Analysis
 
SCP Important Levels Intraday
RESISTANCE0.22
RESISTANCE0.19
RESISTANCE0.17
RESISTANCE0.15
SUPPORT0.09
SUPPORT0.07
SUPPORT0.05
SUPPORT0.02
 
SCP Forecast September 2025
4th UP Forecast0.18
3rd UP Forecast0.16
2nd UP Forecast0.15
1st UP Forecast0.14
1st DOWN Forecast0.1
2nd DOWN Forecast0.09
3rd DOWN Forecast0.08
4th DOWN Forecast0.06
 
SCP Weekly Forecast
4th UP Forecast0.16
3rd UP Forecast0.15
2nd UP Forecast0.14
1st UP Forecast0.13
1st DOWN Forecast0.11
2nd DOWN Forecast0.10
3rd DOWN Forecast0.09
4th DOWN Forecast0.08
 
SCP Forecast2025
4th UP Forecast0.45
3rd UP Forecast0.34
2nd UP Forecast0.28
1st UP Forecast0.21
1st DOWN Forecast0.03
2nd DOWN Forecast-0.04
3rd DOWN Forecast-0.1
4th DOWN Forecast-0.21
 
 
SCP Other Details
Segment EQ
Market Capital 199643728.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
SCP Address
SCP
 
SCP Latest News
 
Your Comments and Response on Scancell Holdings plc
 
SCP Business Profile
Scancell Holdings plc engages in the discovery and development of novel vaccines for the treatment of various cancers. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 that is in phase I/II combination trials for the treatment of non-small cell lung cancer; and Modi-1, which is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2 that is in pre-clinical trial for the treatment of multiple solid tumors. The company has a research collaboration agreement with BioNTech to develop T-cell receptor based therapeutics; licensing and collaboration agreement with ISA Pharmaceuticals B.V. to use ISA's AMPLIVANT adjuvant technology for the development and commercialization of Modi-1; and collaboration agreements with Cobra Biologics, Centre for Research on Global Virus Infections, the University of Nottingham, and the Nottingham Trent University to develop a vaccine for COVID-19. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom. Address: John Eccles House, Oxford, United Kingdom, OX4 4GP
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service